Samsung Bioepis Snags Second Soliris Biosimilar In Europe
As Three Generics From Accord And Extrovis Also Receive CHMP Nods
Samsung Bioepis has seen its SB12 proposed eculizumab biosimilar rival to Soliris endorsed by the EMA’s CHMP. At the same time, three generics also received positive CHMP opinions.
You may also be interested in...
AstraZeneca’s Ultomiris Nears EU Green Light For NMOSD
The UK major’s long-acting C5 inhibitor is nearing EU approval for the debilitating rare disease as the company gears up for emerging competition and loss of exclusivity for its older drug Soliris.
Ultomiris FDA Approval Gives Soliris Biosimilars Bigger Hurdle
Alexion Pharmaceuticals’ Soliris (eculizumab) blockbuster represents a significant opportunity for biosimilar sponsors around the globe. Ahead of anticipated US competition in 2025, the originator has added a new formulation for next-generation product Ultomiris (ravulizumab-cwvz).
Russia’s Generium Announces First Biosimilar Of Soliris
Russia’s Generium has announced its launch of the first biosimilar version of Alexion’s blockbuster orphan-disease drug Soliris, one of the most expensive prescription medicines in the world.